Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07505290
Active, not recruiting Not applicable

Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial for Children With Autism Spectrum Disorder

NCT07505290 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Bundang Hospital
Phase
Not applicable
Started
2026-02-19
Last updated
2026-04-01

Condition(s) studied

Autism Spectrum Disorder

Investigational drug(s) / intervention(s)

The Korean version of PEERS® for Preschoolers (PEERS®-PS-K)

The Korean version of PEERS® for Preschoolers (PEERS®-PS-K): The Korean version of PEERS® for Preschoolers (PEERS®-PS-K) is a 16-week, parent-assisted social skills intervention for preschoolers with ASD. The program consists of weekly 90-minute sessions. Children are taught social skills through puppet shows, role-playing, and structured play, focusing on making friends, playing with peers, and managing conflicts. Concurrently, parents receive coaching sessions to learn how to facilitate their children's social interactions and manage playdates in natural settings. Weekly homework is assigned to generalize the learned skills.

Study summary

This study aims to evaluate the efficacy of the Korean version of the PEERS® for Preschoolers (PEERS®-PS-K), a parent-assisted social skills intervention for preschool-aged children with Autism Spectrum Disorder (ASD). Participants will be randomly assigned to either the intervention group, receiving the PEERS®-PS-K program, or a wait-list control group. The study focuses on improving social skills, such as making friends and interacting with peers, through structured lessons and parent coaching.

Eligibility

Sex
ALL
Min age
4 Years
Max age
6 Years
Healthy volunteers
No
Inclusion Criteria: * Children aged 4 to 6 years (at least 4 years 0 months and less than 7 years diagnosed with Autism Spectrum Disorder (ASD) through standardized diagnostic tools(K-ADOS-2 / K-ADI-R). * Verbal Intelligence Quotient (VIQ) of 70 or higher on the Korean Wechsler Preschool and Primary Scale of Intelligence (K-WPPSI). * Native Korean speakers with sufficient verbal fluency to communicate in full sentences appropriate for their age. * Capable of participating in group activities and language-based interventions as determined through a screening procedure. * Parents or legal guardians who understand the study's purpose and provide voluntary informed consent for both themselves and their child. Exclusion Criteria: * Parents or legal guardians who do not consent to their child's participation in the study. * Presence of intellectual disability or other comorbid psychiatric conditions that may interfere with study participation. * Children exhibiting clinically significant challenging behaviors that could disrupt group sessions. * Other clinically significant neurological, medical, visual, or hearing impairments.

Primary outcome measure(s)

  • Change from Baseline in SRS-2 Total T-score at 16 weeks — Baseline, Post-intervention (16 weeks), and Follow-up (32 weeks)
    The SRS-2 includes five subscales: Social Awareness, Social Cognition, Social Communication, Social Motivation, and Restricted Interests and Repetitive Behavior. Each subscale provides a T-score to identify specific areas of social impairment.

Trial sites (3)

FacilityCityRegionStatus
Kyung Hee University Medical Center Seoul Dongdaemun-gu
Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do
The Catholic University of Korea, Seoul St. Mary's Hospital Seoul Seocho-gu

More Seoul National University Bundang Hospital trials in South Korea

Pepsinogen II and Helicobacter Pylori Test in Gastric Cancer Active, not recruiting
A Study on the Effects of A2 Milk on Gut Beneficial Bacteria Growth and Digestion Improvement Active, not recruiting
Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism Recruiting
Dual-chamber Patient-controlled Analgesia for Postoperative Recovery Recruiting
Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes Recruiting

Other trials for the same condition

A Pilot Study on Efficacy of Digital Therapeutic NDTx-02 for Executive Function in Children and Adolescents With ADHD or ASD Recruiting
Sexuality and Relationship Education Program for Autistic Young Adults in South Korea Active, not recruiting
Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD Recruiting
A Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Children With Developmental Delays Recruiting
Executive Function Training Program for Children With ASD Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07505290 on ClinicalTrials.gov ↗ ← All trials in South Korea